GCIA
BLACU

Gabelli & Co Investment Advisers’s Bellevue Life Sciences Acquisition Corp. Unit BLACU Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio BLACU Stock Details BLACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,800
Closed -$214K – 279
2023
Q1 		$214K Buy
+20,800
New +$213K 0.04% 149

Other funds holding BLACU

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
TAM
Terrapin Asset Management Miami, Florida $87.8M AUM 16.84% 1-Year Est. Return

Gabelli & Co Investment Advisers's BLACU Position: Q2 2023 in Review

Gabelli & Co Investment Advisers sold out of Bellevue Life Sciences Acquisition Corp. Unit (BLACU) in Q2 2023, closing a stake of 20,800 shares — an estimated $214K sold.

Gabelli & Co Investment Advisers first reported a position in BLACU in Q1 2023 and held it in 1 quarter. The position peaked at $214K in Q1 2023. 13 funds tracked by Wall St. Rank hold BLACU as of Q2 2023.

  • Gabelli & Co Investment Advisers reported no remaining Bellevue Life Sciences Acquisition Corp. Unit position as of Q2 2023 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 20,800 Bellevue Life Sciences Acquisition Corp. Unit shares in Q2 2023, an estimated $214K.
  • Gabelli & Co Investment Advisers first reported a position in Bellevue Life Sciences Acquisition Corp. Unit in Q1 2023 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Bellevue Life Sciences Acquisition Corp. Unit position peaked at $214K in Q1 2023.
  • 13 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Unit as of Q2 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.